Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China, Hong Kong, Macau To Modernize Compendium of Materia Medica

This article was originally published in PharmAsia News

Executive Summary

Some 30 experts and academics from China, Hong Kong, Macau, and countries in the region have proposed the Herbalome Project to modernize the Compendium of Materia Medica by using a scientific approach. The China Ministry of Science and Technology is reviewing the project as part of an initiative in the next five-year plan. The international medical community does not accept traditional Chinese medicine due to the lack of functional clarity in the complex compositions; moreover, consumer demand of drug safety and efficacy is rising. The ministry believes that only through scientific theory and methodology in TCM research, as well as building on the effectiveness and composition correlation, can the field be modernized and internationalized. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel